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BACKGROUND
The pathogenic mutations in melanoma have been largely catalogued; however, 
the order of their occurrence is not known.
METHODS
We sequenced 293 cancer-relevant genes in 150 areas of 37 primary melanomas 
and their adjacent precursor lesions. The histopathological spectrum of these areas 
included unequivocally benign lesions, intermediate lesions, and intraepidermal or 
invasive melanomas.
RESULTS
Precursor lesions were initiated by mutations of genes that are known to activate 
the mitogen-activated protein kinase pathway. Unequivocally benign lesions har-
bored BRAF V600E mutations exclusively, whereas those categorized as intermedi-
ate were enriched for NRAS mutations and additional driver mutations. A total of 
77% of areas of intermediate lesions and melanomas in situ harbored TERT pro-
moter mutations, a finding that indicates that these mutations are selected at an 
unexpectedly early stage of the neoplastic progression. Biallelic inactivation of 
CDKN2A emerged exclusively in invasive melanomas. PTEN and TP53 mutations 
were found only in advanced primary melanomas. The point-mutation burden in-
creased from benign through intermediate lesions to melanoma, with a strong 
signature of the effects of ultraviolet radiation detectable at all evolutionary stages. 
Copy-number alterations became prevalent only in invasive melanomas. Tumor 
heterogeneity became apparent in the form of genetically distinct subpopulations 
as melanomas progressed.
CONCLUSIONS
Our study defined the succession of genetic alterations during melanoma progres-
sion, showing distinct evolutionary trajectories for different melanoma subtypes. 
It identified an intermediate category of melanocytic neoplasia, characterized by 
the presence of more than one pathogenic genetic alteration and distinctive histo-
pathological features. Finally, our study implicated ultraviolet radiation as a major 
factor in both the initiation and progression of melanoma. (Funded by the Na-
tional Institutes of Health and others.)
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The Genetic Evolution of Melanoma
Cancer arises through the accumu-lation of genetic alterations that lead to unrestrained cell proliferation. Large-scale 
sequencing projects that catalogue mutations in 
melanoma have been carried out mostly on ad-
vanced tumors, so it is difficult to infer the order 
of mutations. Melanomas often arise from distinc-
tive precursor lesions such as melanocytic nevi, 
intermediate lesions, or melanoma in situ, which 
makes the analysis of their progression possible.
The succession of genetic alterations that leads 
to melanoma is incompletely understood. Somatic 
mutations in dominant melanoma oncogenes such 
as BRAF, NRAS, GNAQ, or GNA11 and rearrange-
ments resulting in fusion kinases are already pres-
ent in benign nevi, indicating that they occur 
early during progression.1-6 However, little is 
known about the sequential order of additional 
mutations that are present in late-stage melano-
mas, including mutations of TERT, CDKN2A, TP53, 
genes encoding SWI/SNF subunits (most com-
monly ARID2), and PTEN, among others.7-14
There has been a long-standing debate about 
the existence of an intermediate category of le-
sions between clearly benign nevi and melano-
ma. This is exemplified by the concept of dys-
plastic nevi, which has remained controversial.15 
Delineating the order of genetic alterations that 
lead to primary melanomas and linking their 
emergence to specific progression stages of the 
primary lesion could yield biomarkers that would 
improve diagnosis and prognostication, because 
such biomarkers would allow the determination 
of how far a given melanocytic neoplasm has 
evolved. A better understanding of the genetic evo-
lution of melanoma could also clarify the existence 
of intermediate lesions, because they would be 
predicted to have more pathogenic mutations than 
benign lesions but fewer than unequivocal mela-
nomas.
Me thods
Cases
A total of 37 formalin-fixed, paraffin-embedded 
(FFPE) melanocytic neoplasms, enriched for 
melanomas with histologically distinct precur-
sors, were retrieved from the archives of the 
Dermatopathology Sections of the University of 
California, San Francisco; St. John’s Hospital in 
London; and the University Hospital of Zurich. 
In total, 150 distinct areas were manually micro-
dissected for sequencing (see Supplementary Ap-
pendix 2, available with the full text of this article 
at NEJM.org). Each area was independently as-
sessed by eight dermatopathologists and grouped 
into one of the following histologic categories: 
benign, intermediate but probably benign, inter-
mediate but probably malignant, or melanoma. 
The American Joint Committee on Cancer staging 
system was used to further stratify melanomas.
Sequencing
For each sample, 25 to 250 ng of DNA was pre-
pared for sequencing with the use of the NuGEN 
Ovation or Bioo Scientific NEXTflex library prep-
aration kits according to the manufacturer’s in-
structions. Formalin fixation and the small 
number of cells in many cases resulted in re-
duced complexity of sequencing libraries with 
high fractions of duplicate reads, as has been 
described previously for similar samples.16-21 To 
achieve the desired sequencing depth of unique 
reads, we elected to perform targeted sequenc-
ing of 293 cancer genes (see Supplementary Ap-
pendix 3). We also analyzed the entire exomes of 
all microdissected samples from two cases with 
the highest library complexities and did not iden-
tify relevant genetic alterations outside the 293-
gene footprint.
Data Analysis
Sequencing reads were mapped and groomed 
with the use of Burrows–Wheeler Aligner, Genome 
Analysis Toolkit, and Picard (http://broadinstitute 
. github . io/ picard/ ). Copy number was inferred 
with the use of CNVkit.22 Neoplastic cellularity 
was estimated from the frequencies of somatic 
and germline variant alleles. Phylogenetic trees 
were constructed manually according to the prin-
ciples of maximum parsimony and were rooted 
at the germline state. Additional details can be 
found in Supplementary Appendix 1.
R esult s
Genetic Evolution from Precursors  
to Melanoma
We obtained an average sequencing coverage of 
281× for the 150 samples, which enabled us to 
identify somatic mutations even in the presence 
of a high level of stromal-cell contamination 
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(average, 64%; range, 15 to 90) (Supplementary 
Appendix 2). We compared mutations and copy-
number changes among the microdissected ar-
eas, sampling multiple instances of histologically 
similar areas as replicates whenever feasible. A 
representative example is shown in Figure 1, in 
which normal, nonlesional tissue was microdis-
sected along with two replicate areas of a nevus 
and two replicate areas of a melanoma (see Fig. 
S1 through S36 in Supplementary Appendix 1 for 
all other cases). For the most part, histologic 
replicates were genetically indistinguishable and 
were combined for analysis as in the example 
case (Fig. 1), with exceptions indicated (e.g., 
Case 25, shown in Fig. S25 in Supplementary 
Appendix 1).
For each case, the mutant allele frequencies 
of all somatic mutations were plotted for the 
precursor and descendant neoplasms (Fig. 1B). 
Fully clonal mutations that were seen in both the 
precursor and descendant neoplasms probably 
occurred early and thus included mutations that 
both initiated neoplastic proliferation and were 
propagated to the more advanced stage or stag-
es. Therefore, the nevus in the example case was 
probably initiated by a BRAF V600E mutation 
(Fig. 1B). In every case, a mutation known to ac-
tivate the mitogen-activated protein kinase (MAPK) 
signaling pathway, usually in BRAF or NRAS, could 
be nominated as the putative initiating onco-
gene (Fig. S1 through S36 in Supplementary 
Appendix 1).
The descendant neoplasms usually harbored 
additional mutations that were not present in 
their precursors and that therefore probably oc-
curred later and included mutations that contrib-
uted to progression. The melanoma in the ex-
ample case (Fig. 1B) probably progressed after 
acquiring a disabling frame-shift mutation in the 
tumor suppressor ARID1A. Progression muta-
tions found in other cases commonly affected 
the TERT promoter (Fig. S2, S3, S9, S21, S25, and 
S27 in Supplementary Appendix 1), CDKN2A (Fig. 
S6, S16, S27, S33, S34, and S36 in Supplemen-
tary Appendix 1), and genes encoding SWI/SNF 
subunits (Fig. S1, S4, S14, S15, S21, and S22 in 
Supplementary Appendix 1). The presence or 
absence of mutations in the TERT promoter 
could not be assessed for eight cases (listed in 
Supplementary Appendix 2) that were analyzed 
before the identification of the TERT promoter as 
a mutational hotspot.9,10
Genomic regions affected by copy-number al-
terations were identified from deviations in read 
depth from a reference pool of normal tissues. In 
the example case (Fig. 1C), both areas of the 
nevus showed no copy-number alterations, 
whereas the two areas of the melanoma showed 
concordant losses of the short arm of chromo-
some 9 with a superimposed homozygous dele-
tion including CDKN2A. As in the example case, 
copy-number alterations were infrequent in be-
nign precursors but common in descendant neo-
plasms. Copy-number alterations that were asso-
ciated with progression in other cases included 
deletions of CDKN2A (Fig. S2, S4, S7, S8, S13, 
S14, S15, S19, S21, S22, S25, S27, S29, S31, S32, 
and S35 in Supplementary Appendix 1), deletions 
of PTEN (Fig. S6, S8, S25, and S28 in Supplemen-
tary Appendix 1), chromosome 7q gains that 
increased gene dosage of mutant BRAF (Fig. S4, 
S23, and S35 in Supplementary Appendix 1), 
and focused amplifications of MDM2 (Fig. S11 
in Supplementary Appendix 1), TERT (Fig. S31 in 
Figure 1 (facing page). The Genetic Evolution  
of Melanoma from a Precursor Nevus (Case 31).
Panel A shows hematoxylin and eosin–stained sec-
tions of normal, nonlesional skin, two areas of benign 
nevus, and two areas of the invasive melanoma that 
were microdissected as indicated. Panel B shows a 
scatterplot of mutant allele frequencies (MAFs) in the 
nevus areas as compared with the melanoma areas. 
The blue lines correspond to the expected allelic fre-
quency of a clonal, heterozygous mutation after we ac-
counted for stromal-cell contamination, with shading 
showing confidence intervals. In Panel C, the heatmap 
depicts copy-number decreases (blue) and increases 
(red) for each sample (rows) across the genome, with 
chromosome boundaries annotated. The inset scatter-
plot shows bin-wise copy number (gray data points); 
segments called with the use of the circular binary 
segmentation (CBS) algorithm are overlayed in or-
ange. The bins overlapping with CDKN2A are indicat-
ed in red. In Panel D, the deviation from the expected 
allelic ratio of 0.5:0.5 of germline heterozygous single-
nucleotide polymorphisms (SNPs) is plotted on the y 
axis and ordered by the position of each SNP across 
the genome on the x axis. Loss of heterozygosity of 
chromosome 9 (CDKN2A) is indicated in purple. As 
shown in Panel E, fluorescence in situ hybridization 
(FISH) and immunohistochemical analysis (IHC) for 
p16 antibody confirmed a stepwise decrease in CDK-
N2A relative to a control probe and a stepwise de-
crease in p16 at the transition to melanoma. CEP de-
notes centromere enumeration probe. Panel F shows 
the inferred evolution of Case 31.
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Supplementary Appendix 1) and YAP1 (Fig. S5 
in Supplementary Appendix 1).
Copy-number alterations introduce allelic im-
balances of germline heterozygous single-nucle-
otide polymorphisms, which are evident as de-
viations from the expected allelic ratio of 0.5:0.5. 
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This is exemplified in the allelic imbalance caused 
by the deletion of one copy of chromosome 9p in 
the melanoma area of the example case (Fig. 1D). 
Allelic imbalances served as independent valida-
tion of copy-number calls for all cases (Fig. S1 
through S36 in Supplementary Appendix 1) but 
also identified regions of copy-number–neutral 
loss of heterozygosity. Copy-number–neutral loss 
of heterozygosity did not occur in the example 
case but was observed in other cases, resulting 
in homozygosity of mutated tumor suppressors 
(Fig. S6, S8, and S34 in Supplementary Appen-
dix 1) or increased gene dosage of oncogenic 
alleles (Fig. S1, S6, S7, S10, S27, S34, and S35 in 
Supplementary Appendix 1).
Whenever feasible, we also attempted to obtain 
independent validation of relevant alterations by 
means of immunohistochemical testing, fluo-
rescence in situ hybridization (FISH), or both 
(Fig. 1E; and Fig. S8, S13, S14, S15, S16, S21, 
S22, S23, S27, S31, S32, and S34 in Supplemen-
tary Appendix 1). As shown in Figure 1E, FISH 
confirmed an intact CDKN2A locus with robust 
protein expression in the nevus areas and com-
plete loss of expression in the melanoma areas 
with homozygous deletion. The flanking areas 
of early invasive melanoma, which were not ana-
lyzed separately by means of sequencing, showed 
a hemizygous deletion on FISH, with correspond-
ing intermediate levels of protein (Fig. 1E).
We partitioned genetic alterations between 
precursor and descendant neoplasms to deduce 
the phylogenetic history of each case. Shared ge-
netic alterations constituted the trunk of the phy-
logenetic tree, whereas private alterations defined 
the branches. The lengths of trunk and branches 
were scaled on the basis of the number of so-
matic mutations, as in the example case (Fig. 1F).
Correlation of Mutation Patterns  
with Histopathological Features
Many melanocytic neoplasms can be classified 
as benign or malignant with a high degree of in-
terobserver agreement. However, there is a gray 
zone of intermediate lesions that are characterized 
by overlapping morphologic criteria and lower in-
terobserver agreement. It is currently unknown 
whether such lesions represent true biologic enti-
ties or merely reflect the limitations of histopatho-
logical assessment. Figure 2 shows the median 
and interquartile range of the observer evalua-
tions for the separate areas from each case. As 
expected, there was a high degree of interob-
server agreement at the ends of the spectrum, 
with a wider range in the intermediate categories.
All 13 areas that were unanimously consid-
ered to be benign showed a BRAF V600E muta-
tion as the only apparent pathogenic mutation 
(Fig. 2). By contrast, 19 of the 21 areas classified 
as intermediate by at least two observers showed 
multiple pathogenic mutations. The intermedi-
ate lesions had a broader spectrum of initiating 
oncogenes than the unequivocally benign le-
sions, including BRAF V600K or K601E and NRAS 
mutations (Fig. 2 and 3A). The intermediate le-
sions also had a higher mutational burden than 
benign lesions (P = 0.03 by Wilcoxon rank-sum 
test) (Fig. 3B). These findings indicate that the 
majority of intermediate lesions that were classi-
fied on morphologic grounds also had genetic 
characteristics that reside between benign and 
malignant neoplasms.
Among melanomas, the frequency of specific 
mutations, patterns of copy-number alterations, 
and mutational burden vary significantly with 
tissue and anatomical site of origin, age at diag-
nosis, and cumulative sun exposure, which has 
led to the recognition that melanomas comprise 
biologically distinct subtypes.5,11 Specifically, mel-
anomas with BRAF V600E mutations are more 
common on intermittently sun-damaged skin of 
younger patients and have distinct histopatho-
logical features,24 whereas melanomas with NRAS 
mutations and BRAF V600K or K601E mutations 
occur predominantly on chronically sun-damaged 
skin of older patients.25 We also observed two dif-
ferent modes of progression, a finding consis-
Figure 2 (facing page). The Genetic Evolution of All 
Cases.
The median (colored circle) and interquartile range 
(colored line) of histopathological evaluations are dis-
played for each area, with respective oncogenic altera-
tions superimposed. Cases are ordered according to 
the stage at diagnosis for the precursor lesion. In two 
cases, a pathogenic mutation was present in the germ-
line. The TERT promoter was not sequenced for the eight 
cases denoted with an asterisk. Underlined oncogenic al-
terations exhibited an ultraviolet-radiation–induced 
mutational signature. Amp denotes amplification, del 
deletion, fs frame shift, het heterozygous, hom homo-
zygous, and LOH loss of heterozygosity. See Figures 
S1 through S36 in Supplementary Appendix 1 for a de-
tailed description of each case.
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Figure 3. Patterns of Mutations and Mutation Burden at Each Stage of Progression.
Panel A shows the distribution of mitogen-activated protein kinase (MAPK) pathway mutations, with stratification according to histolog-
ic stage. Panel B shows the point-mutation burden, as measured by mutations per megabase (Mb), and the burden of copy-number al-
terations (CNAs), as measured by the proportion of the genome altered. Panel C shows the distribution of TERT and CDKN2A altera-
tions by CNAs or mutations. Panel D shows the proportion of point mutations that were induced by ultraviolet radiation ([C/T]C to T). 
Panels E shows the correlation between mutational burden in melanoma areas and sun exposure, as inferred from the age of the patient 
and the anatomical site, and Panel F shows the same correlation as inferred from solar elastosis. Anatomical sites were grouped on the 
basis of sun exposure, as shown on the right side of Panel E. Solar elastosis was scored as described previously,23 with examples on the 
right side of Panel F. BNLM denotes blue nevus–like melanoma, and DM desmoplastic melanoma.
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tent with the diverging features of the lesions. 
Melanomas with BRAF V600E mutations arose 
from benign nevi. By contrast, melanomas with 
NRAS mutations or BRAF V600K or K601E muta-
tions were more commonly associated with inter-
mediate lesions or melanomas in situ that had 
already accumulated other pathogenic mutations.
Two outlier cases in terms of cumulative sun 
exposure further support the notion that the dif-
ferent melanoma subtypes show distinct pro-
gression trajectories. Case 29 was a blue nevus 
that progressed to a blue nevus–like melanoma 
(Fig. S29 in Supplementary Appendix 1), a sun-
shielded melanoma subtype that is genetically 
related to uveal melanoma.1,6,26 The nevus was 
initiated by a GNA11 Q209L mutation as the only 
detectable mutation, and progression to mela-
noma coincided with a subsequent SF3B1 R625H 
mutation and homozygous loss of BAP1. There 
were very few point mutations in the blue nevus–
like melanoma, and they did not exhibit damage 
induced by ultraviolet radiation. Case 8 was a 
melanoma in situ that was associated with des-
moplastic melanoma (Fig. S8 in Supplementary 
Appendix 1), a biologically distinct subtype of 
melanoma that is associated with high cumula-
tive sun exposure and characterized by sarcoma-
tous growth patterns.27 The earliest detectable 
pathogenic mutation was a homozygous splice-
site mutation of NF1 that was already present in 
the in situ area, and progression to desmoplastic 
melanoma coincided with homozygous loss of 
CDKN2A and PTEN. There were numerous point 
mutations reflective of ultraviolet radiation, a 
finding that is consistent with the high sun ex-
posure associated with most desmoplastic mela-
nomas.28
Despite differences in initiating oncogenes, 
there were strong similarities among the later 
mutations that accumulated during subsequent 
stages of progression. TERT promoter mutations 
emerged early in intermediate lesions and mela-
nomas in situ, occurring in 77% of these neo-
plasms (Fig. 3C). Loss of both CDKN2A copies 
was evident exclusively in invasive melanomas 
(Fig. 3C). Mutations in SWI/SNF chromatin re-
modeling genes also emerged predominantly in 
invasive melanomas (Fig. 2). Finally, losses of 
PTEN and TP53 were uncommon in our series 
but occurred exclusively in thicker, invasive mela-
nomas (Fig. 2), findings that imply that these 
mutations may occur later.
Mutational Patterns during Melanoma 
Evolution
The burden of point mutations escalated with 
each histologic stage (Fig. 3B), and the muta-
tions exhibited a signature of the effects of ul-
traviolet radiation across all progression stages 
(Fig. 3D). In the melanoma areas, the burden of 
point mutations correlated with cumulative sun 
exposure as inferred clinically (Fig. 3E) and his-
tologically (Fig. 3F). Copy-number alterations were 
rare in unequivocally benign lesions and were 
present only occasionally in intermediate lesions 
and melanomas in situ (Fig. 3B). In contrast, inva-
sive melanomas invariably harbored copy-num-
ber alterations, affecting larger portions of the 
genome. In aggregate, these results suggest that 
ultraviolet radiation is a dominant mutagen in 
the pathogenesis of sun-exposed melanomas that 
acts throughout all stages of progression, starting 
with the initiation of precursor lesions, whereas 
chromosomal instability arises as an additional 
factor at the transition to the invasive stage.
The distribution of genetic alterations, point 
mutations, and copy-number changes among dif-
ferent areas of individual cases revealed the phy-
logenetic history of each neoplasm. Melanocytic 
neoplasms evolved linearly during the earliest 
stages and exhibited branched evolution as they 
became more advanced (Fig. S37 in Supplemen-
tary Appendix 1).
Discussion
From our data comparing individual primary 
melanomas with melanoma precursor lesions at 
distinct pathologic levels in different patients, 
we inferred a stereotypical pattern of melanoma 
evolution (Fig. 4). Given that an individual tumor 
cannot readily be studied as it progresses from 
benign to malignant, our approach nevertheless 
appeared to reveal a more or less consistent pat-
tern of genetic changes. The progression cascade 
was initiated by mutations known to activate the 
MAPK pathway, which were followed by activation 
of telomerase and disruption of the G1–S check-
point. The mutational signatures implicated ultra-
violet radiation as a dominant pathogenic factor 
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that acts from nevogenesis throughout the more 
advanced histologic stages. The pathogenic role of 
ultraviolet radiation was further supported by the 
ultraviolet-radiation–induced mutational signature 
of several driver mutations (Fig. 2). In aggregate, 
these findings indicate that sun protection should 
reduce melanoma risk, especially among persons 
with a high nevus count.
Our study indicates that different melanoma 
subtypes evolve through distinct trajectories. All 
unequivocally benign lesions harbored BRAF V600E 
as the only apparent pathogenic alteration. Al-
though we did not survey the entire genome, we 
did sequence every bona fide melanoma gene that 
was nominated from large-scale exome studies,7,8
and the absence of additional driver mutations 
implies that BRAF V600E is sufficient to form a 
nevus. By contrast, and unexpectedly, every pre-
cursor lesion with NRAS or other BRAF muta-
tions harbored additional oncogenic alterations, 
and these lesions fell into the intermediate cat-
egory. The biologic differences between benign 
and intermediate precursors most likely reflect 
the divergent evolutionary paths of melanomas 
on skin with chronic sun-induced damage and 
melanomas on skin without such damage.29-31 The 
distinctive evolution of the blue nevus–like mela-
noma and the desmoplastic melanoma further 
support the notion that different subtypes of mela-
nomas have distinct evolutionary trajectories.
The existence of a category of lesions residing 
between clearly benign and clearly malignant 
states has long been proposed but has remained 
controversial. The term “dysplastic nevus” was 
introduced to describe the enlarged acquired 
nevi that are often found in patients who have a 
genetic predisposition to melanoma.32 The clini-
cal phenotype of multiple dysplastic nevi has 
been shown to be a reliable predictor of mela-
noma risk.33,34 However, the relevance of the 
histopathological features that are attributed to 
dysplastic nevi has remained controversial, and 
there is considerable variation in the way in 
which dysplastic nevi are diagnosed and man-
aged clinically.15 We therefore avoided the term 
“dysplastic” in grading individual areas and in-
stead asked the participating pathologists to 
assign each lesion a probability of malignancy. 
Intermediate lesions showed discrete genetic al-
terations, which indicated that they were bio-
logically distinct. However, detailed follow-up 
studies will be necessary to specifically delineate 
their histopathological characteristics and deter-
mine whether genetic or morphologic features 
can be identified that determine the risk of their 
progression to melanoma.
TERT promoter mutations were the earliest 
secondary alterations, already emerging in inter-
mediate lesions and melanomas in situ (Fig. 4). 
The number of cells in these comparatively pauci-
Figure 4. Proposed Models for Progression of Melanomas Developing on Sun-Exposed Sites.
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cellular neoplasms makes it surprising that a ge-
netic alteration that bypasses replicative senes-
cence underwent positive selection. The early 
emergence of TERT mutations suggests that the 
cells in these lesions are or have been dividing 
rather than senescent, with proliferation coun-
terbalanced by attritional factors, such as a cyto-
toxic immune response or cell death or cell-cyle 
arrest due to mitotic errors as a consequence of 
replicative stress.35 This model predicts that once 
the cells of a precursor exhaust their replicative 
potential, this balance would tip in favor of cell 
attrition and result in involution, a well-docu-
mented fate of acquired nevi later in the patient’s 
life.36 By contrast, precursors that acquired TERT 
mutations would persist and could acquire sub-
sequent mutations, with progression toward mel-
anoma.
We found that melanocytic neoplasms transi-
tioned from linear to branched evolution at later 
stages of progression, leading to tumor heteroge-
neity. Polyclonal neoplasms are expected to be 
more resilient to intrinsic defenses of the immune 
system and to therapeutic approaches, which may 
explain the therapeutic success of early removal.
In summary, our study defined the succes-
sion of genetic alterations during melanoma 
progression and can serve as the foundation for 
formulation of refined criteria for diagnosis and 
prognostication. It revealed an intermediate cat-
egory of melanocytic neoplasia, characterized by 
the presence of more than one pathogenic ge-
netic alteration — a finding that helps to resolve 
the decades-long controversy about dysplastic 
nevi. Finally, our study implicated ultraviolet ra-
diation as a major factor in both the initiation and 
progression of melanoma.
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